This field is required
This field is required
The information contained in this section of the website is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into the Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or the United States or any other jurisdiction in which such release, publication or distribution might constitute a violation of the local securities laws or regulations of such jurisdiction.
IMPORTANT INFORMATION
The information in this section of the website pertains to the Rights Issue and due to legal restrictions is not intended for, and must not be directly or indirectly, in whole or in part, accessed by, or distributed or disseminated to persons resident or physically present in Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, the United States or any other jurisdiction where such action is wholly or partially subject to legal restrictions, or would require additional prospectuses, registration or other measures than those required by Swedish law. You are requested to review the following information and make the following confirmation each time you seek to access this restricted information. Your confirmation must be true and accurate.
On June 28th 2023, the board of directors of Moberg Pharma resolved carry out a rights issue of units comprised of shares and warrants in Moberg Pharma with preferential rights for existing shareholders, subject to the subsequent approval of the extraordinary general meeting August 8th, 2023 (the “Rights Issue”).
The information in this section of the website pertains to the Rights Issue and is not intended for, and must not be directly or indirectly, in whole or in part, accessed by, or distributed or disseminated to persons resident or physically present in Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, the United States or any other jurisdiction (“Restricted Jurisdiction”) where such action is wholly or partially subject to legal restrictions, or would require additional prospectuses, registration or other measures than those required by Swedish law. The information in this section of the website does not constitute any offer regarding unit rights, paid subscribed units, shares or warrants issued by Moberg Pharma (“Securities”) to any person in said jurisdictions. Persons who take part of the information in this section of the website and that are subject to the laws and regulations of any such jurisdiction will need to inform themselves about, and observe, any applicable restrictions or requirements. The information in this section of the website may not be forwarded or reproduced in such a manner that contravenes such restrictions or gives cause to such requirements. Actions in violation of these restrictions may constitute a violation of applicable securities laws. To the extent permitted by applicable law, Moberg Pharma disclaims any responsibility or liability for any violations of any such restrictions.
The Securities in Moberg Pharma have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or under any securities laws of any state or other jurisdiction of the United States, and may not be offered, sold or otherwise transferred, directly or indirectly, in or into the United States, unless carried out pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and carried out in accordance with the securities legislation in the relevant state or other jurisdiction of the United States.
The Securities in Moberg Pharma have not been and will not be registered under the applicable securities laws of Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, or any other jurisdiction in which it would be unlawful or would require registration or other measures, and may therefore not be offered or sold on the account or for benefit of any person having a registered address in, or located or resident in, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction in which it would be unlawful or would require registration or other measures.
In any EEA Member State, other than Sweden and Denmark, that has implemented the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (together with any related implementing and delegated regulations, the “Prospectus Regulation”), the information in this section of the website is only addressed to and are only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation.
To access the information contained in this section of Moberg Pharma’s website, all persons must first ensure that they are not subject to legal restrictions that limit their right to access the information in this section of Moberg Pharma’s website.
By selecting “I confirm” below, you confirm that you have read and understood the information, conditions and the instructions above, that you accept to be bound by them, that you are not a resident of, nor located in, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or the United States or any other Restricted Jurisdiction, and that you are a person who is permitted under applicable law and regulation to access the information in this section of the website.